Key facts
- This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Mar 2025, 18:30.
Eric Karas - 20 Mar 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- SPRY
- Reported as of
- 20 Mar 2025
- Net transaction value
- -$125,000
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2025, 18:30:14 UTC
- Prior SEC filing
- 03 Jan 2025
- Next SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 21 Mar 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: -$125,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $15,000
- Shares
- +10,000
- Change %
- +130%
- Price
- $1.50
- Shares after
- 17,696
- Date
- 20 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
SPRY
transaction
Common Stock
Sale
- Transaction value
- $140,000
- Shares
- -10,000
- Change %
- -57%
- Price
- $14.00
- Shares after
- 7,696
- Date
- 20 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -1.7%
- Price
- $0.000000
- Shares after
- 574,588
- Date
- 20 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $1.50
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
Footnote F2
The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
Footnote F3
Immediately exercisable.